Alaa Halawa is Executive Director of Mubadala Capital’s San Francisco Ventures office. Alaa focuses on investing in venture and early growth-stage biotechnology and healthcare technology companies. Alaa focuses on how technology is enhancing the pharmaceutical industry, from drug discovery through clinical trials; how technology - and in particular bio-informatics, artificial intelligence and machine learning is enhancing disease diagnosis and treatment. Alaa joined Mubadala in 2009 where he worked on designing and implementing the strategy to develop a technology cluster in Abu Dhabi focusing on semiconductor research through partnerships with Silicon Valley companies and academic institutions. Alaa then moved to the Bay Area to support the transition of Executive Leadership in one of Mubadala's key assets in Silicon Valley, GlobalFoundries, where he worked on a series of strategic, corporate development and transformation initiatives. Alaa holds an MBA from Cornell University and a Bachelor of Science in Electrical Engineering from University of Jordan. He sits on the board of Neumora, Alloy Therapeutics, Pretzel Therapeutics and Innovaccer.